June 14, 2024

Analysis compares two treatments for schizophrenia patients

Key Points

Key points are not available for this paper at this time.

Abstract

A new analysis examining long‐acting injectable treatment versus an oral antipsychotic has found a significant reduction in relapse in patients with schizophrenia who used the injectable treatment, regardless of the duration of their illness. The research findings are important to build evidence‐based recommendations for clinical care, researchers stated.

AIに質問

Bookmark

Cite This Study

Valerie A. Canady (Fri,) studied this question.

synapsesocial.com/papers/68e64c46b6db6435875dcc7a https://doi.org/https://doi.org/10.1002/mhw.34084

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparative study of relapses in Severe Mental Disorder among the different long-acting injectable treatments available on the market2025
2Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses2024
3Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations2024 · 4 citations
4A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis2026
5Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States2026

AIに質問

Bookmark